NASDAQ Companies

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to […]

– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – […]

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer […]

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that […]

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on […]

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell […]

New products broaden Merit’s leadership in embolotherapy. Full portfolio will be exhibited at the 18thAnnual GEST Meeting May 16-19 in […]

MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) — Today, Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, […]

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing […]

$150 million capital infusion allows Mullen and Bollinger to operate and expand domestic and international commercial sales efforts These commitments […]